CIT ISLET-ALONE PROTOCOLS

CIT-04: LABORATORY MANUAL FOR CENTRAL LABORATORY ASSESSMENTS

VERSION 7.0 JANUARY 18, 2012 Confidential

The information contained herein is the property of the CIT and may not be reproduced, published, or disclosed to others without written authorization of NIAID / NIDDK.

TABLE OF CONTENTS

1. ADDITIONAL STUDY CONTACT INFORMATION	3
2. CIT-04 CENTRAL LABORATORY SPECIMEN SCHEDULE	4
3. THROMBIN-ANTITHROMBIN COMPLEX (TAT), C3a, AND C-PEPTIDE	7
4. BELATACEPT TROUGH LEVEL	7
5. IMMUNOGENICITY SAMPLE	8
6. CIT-04 KIT COMPONENTS	9
6. CIT-04 MAXIMUM RESEARCH BLOOD VOLUME TABLE	15

List of Appendices

16
17
21
24
26
28

1. ADDITIONAL STUDY CONTACT INFORMATION

PPD Development	Tandem Labs	Protocol Coordinator
Attn: Maria Edwards	Attn: Dania Yaskanin	Cynthia Diltz, RN, BSN, CCRC
2244 Dabney Rd	115 Silvia Street	University of Iowa
Richmond, VA 23230	West Trenton, NJ 08628	Department of Biostatistics
Phone: 804-359-1900	Phone: 609-228-0243	Clinical Trials Statistical and Data
Fax: 804-253-1104	Fax: 609-434-1028	Management Center
		2400 University Capitol Centre
		Iowa City, IA USA 52242-5500
		Phone: +1-319-353-4982
		Fax: +1-319-353-3960
		cynthia-diltz@uiowa.edu

2. CIT-04 CENTRAL LABORATORY SPECIMEN SCHEDULE

	Central Laboratory Assessments					
Assessment	Laboratory	Visit / Time-point	Volume	Collection Container	Shipping Instructions	
Albumin/Creatinine Ratio	University of Minnesota	V08,10,21 (Subs Tx Day 75 ³ , Day 365) ² [V56, 63] ⁶	5 mL Urine	Sterile Urine Container	Ship in batches weekly, frozen on dry ice. Ship on Monday – Thursday.	
Alloantibodies	University of Pennsylvania	V03,10,15,18,21 (V24,27,30) ¹ (Subs Tx Day 0, 75 ³ , 365) ² [V56, 63] ⁶	2 mL Blood	(1) 3-mL Red-top Vacutainer	Ship on dry ice in batches at least quarterly. Ship Monday – Thursday only.	
Atherogenic Profile	University of Washington	V21 (Sub Tx Day 365) ² [V63] ⁶	8.5 mL Blood	(1) 8.5 mL Gold SST	Ship on dry ice in batches at least weekly. Ship Monday – Thursday only.	
Autoantibodies	Barbara Davis Center	V10,15,18,21 (V24,27,30) ¹ (Subs Tx Day 75 ³ , 365) ² [V56, 63] ⁶	2 mL Blood	(1) 3-mL Red-top OR(1) 3.5 mL Tiger top SST	Ship on dry ice in batches at least quarterly .Ship Monday – Wednesday only. If collected on Thursday or Friday, freeze serum at -20°C or -70°C until Monday, Tuesday, or Wednesday.	
Belatacept Trough Level	PPD Development	V04,05,06,07,08,09,10 11,12,13,14,15,16,17,18,19, 20,21 (V22,23,24,25,26,27, 28,29,30) ¹ (Subs Tx Day 4, 7, 75 ³ , 365) ² [V51,52,53,54,55,56,57,58, 59,60,61,62,63] ⁶	2 mL Blood	(1) 3.5 mL Gold SST	Ship in batches bi-monthly on dry ice. Ship Monday – Thursday.	
Fasting serum glucose and c-peptide / serum creatinine	University of Washington	V08,09,10 ⁴ ,12,13,14, 15,16,17,18,19,20,21 (V22,23,24,25,26,27, 28,29,30) ¹ (Subs Tx Day 75 ³ , 365) ² [V56,63,64] ⁶	2 mL Blood	(1) 3.5-mL Gold SST	Ship on dry ice in batches at least weekly. Ship Monday – Thursday only.	

		Ce	ntral Laboratory Assessments		
Assessment	Laboratory	Visit / Time-point	Volume	Collection Container	Shipping Instructions
GFR	University of Minnesota	V08,10,21 (Subs Tx Day 75 ³ , 365) ² [V63] ⁶	10 mL Blood 2 mL each at 120, 150, 180, 210 and 240 minutes	(5) 2-mL Na Heparin Tube	Ship in batches weekly on dry ice. Ship Monday – Thursday
Hemoglobin A1c (HbA1c)	University of Washington	V10,15,18,21, (V24,27,30) ¹ (Subs Tx Day 75 ³ , 365) ² [V53, 56, 60, 63, 64] ⁶	2 mL Blood	(1) 2-mL Lavender top EDTA Vacutainer	Ship on cold pack within 24 hours of collection. Ship Monday-Thursday only.
Immunogenicity Sample	Tandem Labs	V02,14,21 (V27) ¹ (Subs Tx Day 365) ² [V63, 64] ⁶	4 mL Blood	(1) 4-mL Gold SST	Ship in batches quarterly on dry ice. Ship Monday – Wednesday
Insulin Modified FSIGT	University of Washington	V10 ⁴ ,21 (Subs Tx Day 75 ³ , 365) ²	48 mL Total Blood 2 mL each at -10, -5, and -1 minutes pre-injection of glucose 2 mL each at 1, 2, 3, 4, 5, 7, 10, 12, 14, 16, 18, 20, 22, 25, 30, 40, 50, 70, 100, 140, and 180 minutes post injection of glucose	(24) 3.5-mL Gold SST	Ship on dry ice in batches at least weekly. Ship Monday – Thursday only.
MMTT: Stimulated serum glucose and c-peptide	University of Washington	V10 ⁴ ,15,18,21 (V24,27,30) ¹ (Subs Tx Day 75 ³ , 365) ² [V56, 63, 64] ⁶	 4 mL Total Blood 2 mL at 60 minutes (<i>ONLY if checking for graft failure</i>) 2 mL at 90 minutes (Note: the Fasting serum glucose and c-peptide/serum creatinine is the 0 hour sample for the MMTT) 	(2) 3.5-mL Gold SST	Ship on dry ice in batches at least weekly. Ship Monday – Thursday only.
PBMC / Plasma to Archive	ITN Central Cell Processing Core Facility	V10,15,18,21 (V24,27,30) ¹ (Subs Tx Day 75 ³ , 365) ²	30 mL Blood	(3) 10-mL Na Heparin Tube	Ship ambient daily.
RNA to Archive	Expression Analysis	V10,15,18,21 (V24,27,30) ¹ (Subs Tx Day 75 ³ , 365) ²	9 mL Blood	(3) 3-mL Tempus RNA Tube	Ship in batches quarterly on dry ice.

		Cen	tral Laboratory Assessments		
Assessment	Laboratory	Visit / Time-point	Volume	Collection Container	Shipping Instructions
Serum to Archive	NIDDK Repository	V10,15,18,21 (V24,27,30) ¹ (Subs Tx Day 75 ³ , 365) ²	4 mL Blood	(1) 4-mL Gold SST	Ship in batches at least quarterly.
TAT Complex, C3a, c-peptide	Rudbeck Laboratory	V03 ⁵ (Subs Tx Day 0) ²	10 mL Total Blood @ V03 2 mL at Pre-immunosuppression, immediately pre-tx, 15, 60, 180 min post-tx	(5) 2-mL Lavender top EDTA Vacutainer	Ship on dry ice (minimum 5 kg) in batches at least quarterly.

¹Visits as needed for subsequent islet transplant(s). See Appendix 2 – Year Two Schedule of Events ²Endpoint assessments for subsequent transplant(s). See Appendix 3 – Subsequent Transplant Schedule of Events ³If third transplant occurs less than 75 days after the second transplant, the 75 day endpoint data for the second transplant will not be collected

⁴Do not collect these samples at Day 75 for subjects with confirmed graft failure ⁵Collect these samples beginning on Day -2 (pre-IS) for Visit 03

⁶1-Year Additional Follow-up

3. THROMBIN-ANTITHROMBIN COMPLEX (TAT), C3a, AND C-PEPTIDE

- Refer to the General Lab manual for instructions regarding blood draws, processing and shipping
- Subjects randomized to CIT-04 do not receive immunosupression on Day -2. For those subjects, the Pre Immunosuppression sample, labeled Pre IS, is drawn on day 0 prior to the administration of Belatacept, Daclizumab or MMF; the Pre-Transplant sample, labeled Pre-Tx, is drawn immediately prior to the start of the islet infusion

4. BELATACEPT TROUGH LEVEL

- Complete test **prior to** Belatacept infusion.
- Collect 2 ml Blood into 3.5 ml Gold Serum Separator (SST) tube
- Allow to clot at room temperature for 15 30 minutes
- Centrifuge for 15 minutes at 1000 xg (approximately 3000 RPM) in a refrigerated centrifuge
- Transfer at least 0.5 ml serum into a purple cap cryovial
- Immediately freeze at -20° C or colder
- Follow packing instructions outlined in section 4 of General Lab Manual
- Ship samples monthly on dry ice. If shipping from Canada to U.S., please complete an Expanded Service International Air Waybill (With Dry Ice) (Appendix 5 in General Lab Manual)
- On the day of the shipment, print the Specimen List by clicking the View Shipping Report button in the Specimen Tracking System and place a copy in the shipping box. <u>NOTE: you</u> <u>will need to expand the columns in the specimen list to show all the data before printing</u>. An automatic email will be sent to:

Susan.Steever@bms.com

MG-PK-Manifest@bms.com

maria.edwards@richmond.ppdi.com

Kathy.zelinsky@bms.com Mehmooda.shaikh@bms.com

- If you are unable to print the Specimen List from the Specimen Tracking System on the day of shipment, complete a Specimen Submission Form and fax a copy of the form including the airbill tracking number to the laboratory at +1-804-253-1104.
- Shipments must be made Monday through Thursday.

PPD Development Attn: Maria Edwards 2244 Dabney Rd Richmond, VA 23230 Tel: 804-359-1900 Fax: 804-253-1104

5. IMMUNOGENICITY SAMPLE

- Collect immunogenicity samples **prior to** belatacept infusion. For subjects who discontinue belatacept, collect additional immunogenicity samples at 4 weeks and 8 weeks post last dose.
- Collect 4 ml Blood into 4ml Gold Serum Separator (SST) tube
- Allow to clot at room temperature for 15 30 minutes
- Centrifuge for 15 minutes at 1000 xg (approximately 3000 RPM) in a refrigerated centrifuge
- Transfer at least 2 ml serum into a white cap cryovial
- Immediately freeze at -20° C or colder
- Follow packing instructions outlined in section 4 of General Lab Manual
- Ship samples quarterly on dry ice. If shipping from Canada to U.S., please complete an Expanded Service International Air Waybill (With Dry Ice) (Appendix 5 in General Lab Manual)
- On the day of the shipment, print the Specimen List by clicking the View Shipping Report button in the Specimen Tracking System and place a copy in the shipping box. <u>NOTE: you</u> <u>will need to expand the columns in the specimen list to show all the data before printing</u>. An automatic email will be sent to:

Susan.Steever@bms.com zoe.tzogas@bms.com Leec4@labcorp.com albanej@labcorp.com mcgrata@labcorp.com Mehmooda.shaikh@bms.com Yaskand@Labcorp.com

- If you are unable to print the Specimen List from the Specimen Tracking System on the day of shipment, complete a Specimen Submission Form and fax a copy of the form including the airbill tracking number to the laboratory at +1-804-253-1104.
- Shipments must be made Monday through Wednesday.

Tandem Labs Attn: Dania Yaskanin 115 Silvia Street West Trenton, NJ 08628 Phone: 609.228.0243 Fax: 609.434.1028

Note: On visits 14 and 21 you will need to draw both the Belatacept Trough Level and the Immunogenicity sample. On these 2 visits you can draw 5 mL of blood in 1 - 5mL SST tube. Then follow the processing directions in sections 3&4, aliquot 0.5 mL serum in the purple cap cryovial and 2 mL into the white cap cryovial. Shipper above instructions.

6. CIT-04 KIT COMPONENTS

	r		T 1 1 1
VISIT 03 Day 0	KIT #3	TAT, C3a, C-Peptide (5) 2-mL EDTA Vacutainer Tube (5) 1.8-mL Cyrogenic Vial Alloantibody (1) 3-mL Red-top Vacutainer Tube (1) 1.8 mL Cryogenic Vial	Immunogenicity sample (1) 4-mL Gold SST (1) 4.0-mL white cap Cryogenic Vial
VISIT 04 – 07 Day 4, 7, 14, 21 [Subs Tx Day 4, 7] (if needed)	KIT #4	Belatacept Trough Level (1) 3.5-mL Gold SST (1) 1.8-mL purple cap Cryogenic Vi	al
VISIT 08 Day 28	KIT #5	Fasting Serum Glucose, C-Peptide, Creatinine (1) 3.5-mL Gold SST (2) 1.8-mL Cryogenic Vials Albumin/Creatinine Ratio (1) Urine Specimen Container (1) 4.0-mL Cryogenic Vial	GFR (5) 2-mL Na Heparin Tubes (5) 1.8-ml Cryogenic Vials Belatacept Trough Level (1) 3.5-mL Gold SST (1) 1.8-mL purple cap Cryogenic Vial
VISIT 09 Days 56	KIT #6	Fasting Serum Glucose, C-Peptide, Creatinine (1) 3.5-mL Gold SST (2) 1.8-mL Cryogenic Vials	Belatacept Trough Level (1) 3.5 mL Gold SST (1)1.8-mL purple cap Cryogenic Vial
VISIT 10 Day 75 Secondary Endpoint [Subs Tx Day 75] (if needed)	KIT #7	 ¹Fasting Serum Glucose, C-Peptide, Creatinine 3.5-mL Gold SST 1.8-mL Cryogenic Vials ^{1.2}MMTT : Stimulated Glucose and C-peptide 3.5-mL Gold SST 1.8-mL Cryogenic Vials HBA1C 2-mL EDTA Vacutainer Tube Albumin/Creatinine Ratio Urine Specimen Container 4.0-mL Cryogenic Vial ¹FSIGT 3.5-mL Gold SST 8.1.8-mL Cryogenic Vials 	GFR (5) 2-mL Na Heparin Tubes (5) 1.8 ml Cryogenic Vials Alloantibody (1) 3-mL Red-top Vacutainer Tube (1) 1.8 mL Cryogenic Vial Autoantibody (1) 3-mL Red-top Vacutainer Tube (1) 3-mL Red-top Vacutainer Tube (1) 3-mL Red-top Vacutainer Tube (1) 3-mL Cryogenic Vial Serum to Archive (1) 4-mL Gold SST Tube (3) 1.8-mL Cryogenic Vials RNA to Archive (NIDDK) (3) 3-mLTempus RNA Tube PBMC and Plasma to Archive (3) 10-mL Na Heparin Vacutainer tubes Belatacept Trough Level (1) 3.5-mL Gold SST (1) 1.8-mL purple cap Cryogenic Vial
VISIT 11	KIT #4	Belatacept Trough Level (1) 3.5-mL Gold SST (1) 1.8 mL number con Crucesnia Vi	al
Day 84		(1) 1.8-mL purple cap Cryogenic Vi	aı

Clinical Islet Tran Protocol CIT-04 V			CONFIDENTIAL January 18, 2012
VISIT 12,13 Day 112, 140	KIT #6	Fasting Serum Glucose, C-Peptide, Creatinine (1) 3.5-mL Gold SST (2) 1.8-mL Cryogenic Vials	Belatacept Trough Level (1) 3.5 mL Gold SST (1)1.8-mL purple cap Cryogenic Vial
VISIT 14 Day 168	Kit #8	Fasting Serum Glucose, C-Peptide, Creatinine (1) 3.5-mL Gold SST (2) 1.8-mL Cryogenic Vials	Belatacept Trough Level /Immunogenicity sample (1) 5-mL Gold SST (1) 1.8-mL purple cap Cryogenic Vial (1) 4.0-mL white cap Cryogenic Vial
VISIT 15 Day 196	KIT #9	Fasting Serum Glucose, C-Peptide, Creatinine (1) 3.5-mL Gold SST (2) 1.8-mL Cryogenic Vials ² MMTT: Stimulated Glucose and C-peptide (2) 3.5-mL Gold SST (4) 1.8-mL Cryogenic Vials HBA1C (1) 2-mL EDTA Vacutainer Tube	Alloantibody (1) 3-mL Red-top Vacutainer Tube (1) 1.8 mL Cryogenic Vial Autoantibody (1) 3-mL Red-top Vacutainer Tube (1) 3-mL Red-top Vacutainer Tube (1) 1.8 mL Cryogenic Vial Serum to Archive (1) 4-mL Gold SST Vacutainer Tube (3) 1.8-mL Cryogenic Vials RNA to Archive (NIDDK) (3) 3-mLTempus RNA Tube PBMC and Plasma to Archive (3) 10 mL Na Heparin Vacutainer tubes Belatacept Trough Level (1) 3.5 mL Gold SST (1) 1.8-mL purple cap Cryogenic Vial
VISIT 16, 17 Days 224, 252	KIT #6	Fasting Serum Glucose, C-Peptide, Creatinine (1) 3.5-mL Gold SST (2) 1.8-mL Cryogenic Vials	Belatacept Trough Level (1) 3.5 mL Gold SST (1)1.8-mL purple cap Cryogenic Vial
VISIT 18 Day 280	KIT #9	Fasting Serum Glucose, C-Peptide, Creatinine (1) 3.5-mL Gold SST (2) 1.8-mL Cryogenic Vials ² MMTT: Stimulated Glucose and C-peptide (2) 3.5-mL Gold SST (4) 1.8-mL Cryogenic Vials HBA1C (1) 2-mL EDTA Vacutainer Tube	Alloantibody (1) 3-mL Red-top Vacutainer Tube (1) 1.8 mL Cryogenic Vial Autoantibody (1) 3-mL Red-top Vacutainer Tube (1) 1.8 mL Cryogenic Vial Serum to Archive (1) 4-mL Gold SST Vacutainer Tube (3) 1.8-mL Cryogenic Vials RNA to Archive (NIDDK) (3) 3-mLTempus RNA Tube PBMC and Plasma to Archive (3) 10 mL Na Heparin Vacutainer tubes Belatacept Trough Level (1) 3.5 mL Gold SST (1) 1.8-mL purple cap Cryogenic Vial
VISIT 19, 20 Days 308, 336	KIT #6	Fasting Serum Glucose, C-Peptide, Creatinine (1) 3.5-mL Gold SST (2) 1.8-mL Cryogenic Vials	Belatacept Trough Level (1) 3.5 mL Gold SST (1)1.8-mL purple cap Cryogenic Vial

Clinical Islet Trans Protocol CIT-04 V			CONFIDENTL January 18, 201
VISIT 21 Day 365 / Month 12 Secondary Endpoint Subs Tx Day 365 (if needed)	KIT #10	 Fasting Serum Glucose, C-Peptide, Creatinine 3.5-mL Gold SST 1.8-mL Cryogenic Vials ²MMTT: Stimulated Glucose and C-peptide 3.5-mL Gold SST 1.8-mL Cryogenic Vials HBA1C 2-mL EDTA Vacutainer Tube Albumin/Creatinine Ratio Urine Specimen Container 4.0-mL Cryogenic Vial FSIGT 3.5-mL Gold SST 3.5-mL Gold SST (2) 3.5-mL Gold SST (3.5-mL Gold SST (4) 3.5-mL Gold SST (58) 1.8-mL Cryogenic Vials Atherogenic Profile 8.5 mL Gold SST 1.8 mL Cryogenic Vials 	GFR (5) 2-mL Green-top Vacutainer Tubes (5) 1.8-ml Cryogenic Vials Alloantibody (1) 3-mL Red-top Vacutainer Tube (1) 1.8 mL Cryogenic Vial Autoantibody (1) 3-mL Red-top Vacutainer Tube (1) 1.8 mL Cryogenic Vial Serum to Archive (1) 4-mL Gold SST Vacutainer Tube (3) 1.8-mL Cryogenic Vials RNA to Archive (NIDDK) (3) 3-mLTempus RNA Tube PBMC and Plasma to Archive (3) 10-mL Na Heparin Vacutainer tubes Belatacept Trough Level /Immunogenicity sample (1) 5-mL Gold SST (1) 1.8-mL purple cap Cryogenic Vial (1) 4.0-mL white cap Cryogenic Vial
VISIT 22, 23 Day 392, 420	KIT #6	Fasting Serum Glucose, C-Peptide, Creatinine (1) 3.5-mL Gold SST (2) 1.8-mL Cryogenic Vials	Belatacept Trough Level (1) 3.5 mL Gold SST (1)1.8-mL purple cap Cryogenic Vial
VISIT 24 Day 448	KIT #9	Fasting Serum Glucose, C-Peptide, Creatinine (1) 3.5-mL Gold SST (2) 1.8-mL Cryogenic Vials ² MMTT: Stimulated Glucose and C-peptide (2) 3.5-mL Gold SST (4) 1.8-mL Cryogenic Vials HBA1C (1) 2-mL EDTA Vacutainer Tube	Alloantibody (1) 3-mL Red-top Vacutainer Tube (1) 1.8 mL Cryogenic Vial Autoantibody (1) 3-mL Red-top Vacutainer Tube (1) 3-mL Red-top Vacutainer Tube (1) 1.8 mL Cryogenic Vial Serum to Archive (1) 4-mL Gold SST Vacutainer Tube (3) 1.8-mL Cryogenic Vials RNA to Archive (NIDDK) (3) 3-mLTempus RNA Tube PBMC and Plasma to Archive (3) 10 mL Na Heparin Vacutainer tubes Belatacept Trough Level (1) 3.5 mL Gold SST (1) 1.8-mL purple cap Cryogenic Vial
VISIT 25, 26 Day 476, 504	KIT #6	Fasting Serum Glucose, C-Peptide, Creatinine (1) 3.5-mL Gold SST (2) 1.8-mL Cryogenic Vials	Belatacept Trough Level (1) 3.5 mL Gold SST (1)1.8-mL purple cap Cryogenic Vial

Protocol CIT-04 Ve			January 18, 2012
VISIT 27 Day 532	Kit #11	Fasting Serum Glucose, C-Peptide, Creatinine (1) 3.5-mL Gold SST (2) 1.8-mL Cryogenic Vials ² MMTT: Stimulated Glucose and C-peptide (2) 3.5-mL Gold SST (4) 1.8-mL Cryogenic Vials HBA1C (1) 2-mL EDTA Vacutainer Tube	Alloantibody (1) 3-mL Red-top Vacutainer Tube (1) 1.8 mL Cryogenic Vial Autoantibody (1) 3-mL Red-top Vacutainer Tube (1) 3-mL Red-top Vacutainer Tube (1) 1.8 mL Cryogenic Vial Serum to Archive (1) 4-mL Gold SST Vacutainer Tube (3) 1.8-mL Cryogenic Vials RNA to Archive (NIDDK) (3) 3-mLTempus RNA Tube PBMC and Plasma to Archive (3) 10-mL Na Heparin Vacutainer tubes Belatacept Trough Level /Immunogenicity sample (1) 5-mL Gold SST (1) 1.8-mL purple cap Cryogenic Vial (1) 4.0-mL white cap Cryogenic Vial
VISIT 28, 29 Day 560, 588	KIT #6	Fasting Serum Glucose, C-Peptide, Creatinine (1) 3.5-mL Gold SST (2) 1.8-mL Cryogenic Vials	Belatacept Trough Level (1) 3.5 mL Gold SST (1)1.8-mL purple cap Cryogenic Vial
VISIT 30 Day 616	KIT #9	Fasting Serum Glucose, C-Peptide, Creatinine (1) 3.5-mL Gold SST (2) 1.8-mL Cryogenic Vials ² MMTT: Stimulated Glucose and C-peptide (2) 3.5-mL Gold SST (4) 1.8-mL Cryogenic Vials HBA1C (1) 2-mL EDTA Vacutainer Tube	 Alloantibody (1) 3-mL Red-top Vacutainer Tube (1) 1.8 mL Cryogenic Vial Autoantibody (1) 3-mL Red-top Vacutainer Tube (1) 3-mL Red-top Vacutainer Tube (1) 1.8 mL Cryogenic Vial Serum to Archive (1) 4-mL Gold SST Vacutainer Tube (3) 1.8-mL Cryogenic Vials RNA to Archive (NIDDK) (3) 3-mLTempus RNA Tube PBMC and Plasma to Archive (3) 10 mL Na Heparin Vacutainer tubes Belatacept Trough Level (1) 3.5 mL Gold SST (1) 1.8-mL purple cap Cryogenic Vial
Visit 51, 52 M13 (post final tx), M14 (post final tx)	KIT #4	Belatacept Trough Level (1) 3.5-mL Gold SST (1) 1.8-mL purple cap Cryogenic Vial	
Visit 53 M15 (post final tx)	KIT #13	Belatacept Trough Level (1) 3.5-mL Gold SST (1) 1.8-mL purple cap Cryogenic Vial	HBA1C (1) 2-mL EDTA Vacutainer Tube
Visit 54, 55 M16 (post final tx), M17 (post final tx)	KIT #4	Belatacept Trough Level (1) 3.5-mL Gold SST (1) 1.8-mL purple cap Cryogenic Vial	

Clinical Islet Transplantation

Clinical Islet Transp Protocol CIT-04 Ve			CONFIDENTIAL January 18, 2012
Visit 56 M18 (post final tx)	KIT #14	Albumin/Creatinine Ratio (1) Urine Specimen Container (1) 4.0-mL Cryogenic Vial HBA1C (1) 2-mL EDTA Vacutainer Tube Belatacept Trough Level (1) 3.5-mL Gold SST (1) 1.8-mL purple cap Cryogenic Vial	Fasting Serum Glucose, C-Peptide, Creatinine(1) 3.5-mL Gold SST(2) 1.8-mL Cryogenic Vials ² MMTT: Stimulated Glucose and C- peptide(2) 3.5-mL Gold SST(4) 1.8-mL Cryogenic VialsAlloantibody(1) 3-mL Red-top Vacutainer Tube(1) 1.8 mL Cryogenic VialAutoantibody(1) 3-mL Red-top Vacutainer Tube(1) 3-mL Red-top Vacutainer Tube(1) 1.8 mL Cryogenic VialAutoantibody(1) 3-mL Red-top Vacutainer Tube(1) 1.8 mL Cryogenic Vial
Visit 57, 58, 59 M19 (post final tx), M20 (post final tx) TBD (extra visit)	KIT #4	Belatacept Trough Level (1) 3.5-mL Gold SST (1) 1.8-mL purple cap Cryogenic Vial	
Visit 60 M21 (post final tx)	KIT #13	Belatacept Trough Level (1) 3.5-mL Gold SST (1) 1.8-mL purple cap Cryogenic Vial	HBA1C (1) 2-mL EDTA Vacutainer Tube
Visit 61, 62 M22 (post final tx), M23 (post final tx)	KIT #4	Belatacept Trough Level (1) 3.5-mL Gold SST (1) 1.8-mL purple cap Cryogenic Vial	
Visit 63 M24 (post final tx)	KIT #15	Albumin/Creatinine Ratio (1) Urine Specimen Container (1) 4.0-mL Cryogenic Vial HBA1C (1) 2-mL EDTA Vacutainer Tube GFR (5) 2-mL Green-top Vacutainer Tubes (5) 1.8-ml Cryogenic Vials Atherogenic Profile (1) 8.5 mL Gold SST (4) 1.8 mL Cryogenic Vials Fasting Serum Glucose, C-Peptide, Creatinine (1) 3.5-mL Gold SST (2) 1.8-mL Cryogenic Vials	 ²MMTT: Stimulated Glucose and C-peptide (2) 3.5-mL Gold SST (4) 1.8-mL Cryogenic Vials Alloantibody (1) 3-mL Red-top Vacutainer Tube (1) 1.8 mL Cryogenic Vial Autoantibody (1) 3-mL Red-top Vacutainer Tube (1) 1.8 mL Cryogenic Vial Belatacept Trough Level /Immunogenicity sample (1) 5-mL Gold SST (1) 1.8-mL purple cap Cryogenic Vial (1) 4.0-mL white cap Cryogenic Vial
Visit 64 Y2 (post initial tx)	KIT#16	HBA1C (1) 2-mL EDTA Vacutainer Tube Immunogenicity sample (1) 4-mL Gold SST (1) 4.0-mL white cap Cryogenic Vial	Fasting Serum Glucose, C-Peptide, Creatinine(1) 3.5-mL Gold SST(2) 1.8-mL Cryogenic Vials ² MMTT: Stimulated Glucose and C- peptide(2) 3.5-mL Gold SST(4) 1.8-mL Cryogenic Vials

Clinical Islet Transp Protocol CIT-04 Ve			CONFIDEN January 18,
4 or 8 weeks post last dose of Belatacept	KIT #12	Immunogenicity sample wee (1) 4-mL Gold SST (1) 4.0-mL white cap Cryogenic Via (note which visit on the requisition	- 1
Reduced Follow- Up (Year 1 and 2 post Initial transplant)	KIT #50	 90 min C-peptide post MMTT, Serum Creatinine 3.5-mL Gold SST 1.8-mL Cryogenic Vials 	HBA1C (1) 2-mL EDTA Vacutainer Tube Alloantibody (1) 3-mL Red-top Vacutainer Tube (1) 1.8-mL Cryogenic Vial
Reduced Follow-	KIT #50X	Alloantibody (1) 3-mL Red-top Vacutainer Tube	

Reduced Follow- Up (Monthly and	KIT #50X	Alloantibody (1) 3-mL Red-top Vacutainer Tube (1) 1.8-mL Cryogenic Vial	
Quarterly)			
Subs Tx Day 0	KIT #51	TAT, C3a, C-Peptide (5) 2-mL EDTA Vacutainer Tube (5) 1.8-mL Cyrogenic Vial	Alloantibody (1) 3-mL Red-top Vacutainer Tube (1) 1.8 mL Cryogenic Vial
(if needed)			
Suspected Graft Failure	Kit 50Z	Fasting Serum Glucose, C-Peptide, Creatinine (1) 3.5-mL Gold SST (2) 1.8-mL Cryogenic Vials MMTT: Stimulated Glucose and	Alloantibody (1) 3-mL Red-top Vacutainer Tube (1) 1.8 mL Cryogenic Vial Autoantibody (1) 3-mL Red-top Vacutainer Tube
		C-peptide (2) 3.5-mL Gold SST (4) 1.8-mL Cryogenic Vials	(1) 1.8 mL Cryogenic Vial

¹Do not collect these samples at Day 75 for subjects with confirmed graft failure

²The kit contains two 3.5mL Gold SST tubes for the MMTT. Only one of these two tubes will be filled (at 90 minutes), unless it is suspected that the subject has suffered graft failure (in which case, the second tube should be filled at 60 minutes). If there is no suspicion of graft failure, the 60 minute tube and aliquots associated with the 60 minute draw can be discarded

See Appendix 1 for Kit Supply Order Form

CONFIDENTIAL January 18, 2012

6. CIT-04 MAXIMUM RESEARCH BLOOD VOLUME TABLE

			CI	Г04 - І	MAX	IMUI	M RE	SEAF	RCHI	BLOO	DD V	OLUI	ME T.	ABLE	2							
							TIM	E PO	INTS/	VISIT	s											
			Days											Weeks								
TIMING OF STUDY																						
PARTICIPATION	SCRN	BL	TX 0	3	4	1	2	3	4	8	(Day 75)	12	16	20	24	28	32	36	40	44	48	52
VISIT	1	2	3	- 3a	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21
							BI	OOD	VOLU	UMES												
					L	OCAI	LAB	ORAT	ORY	ASSE	SSME	NTS										
CBC (WBC + Diff & Plat)	5	5	5			5	5	5	5	5	5		5	5		5			5			5
Chemistry (P18 + Mg or P20)	4	4	4			4	4	4	4	4	4		4	4		4			4			4
Lipids	4	4									4					4			4			4
Thyroid Function	4	4																				
Serum b-HCG (females)	4	4			4		4		4	4		4	4	4	4	4	4	4	4	4	4	4
PSA	4	4																				4
Serology	7	7																				
EBV IgG	2																					
CMV IgG, CMV IgM		4																				
Coagulation (PT, PTT, INR)	5	5	5																			
Blood Type & HLA		11																				
Crossmatch		10																				
PRA by flow cytometry (Sub Tx)		10																				
Fasting and 2 post-prandial (1-3 hrs) c-pep				9		9																
CMV by PCR		4									4				4							
EBV py PCR 4																						
CENTRAL LABORATORY AND METABOLIC ASSESSMENTS																						
GFR (5 timed specimens/timept; 2 ml each)	10	10							10		10											10
HbAlc (central + local)	4	4									4					4			4			4
Fasting glucose & c-pep / serum creatinine	2	2							2	2	2		2	2	2	2	2	2	2	2	2	2
Insulin modified FSIGT (c-pep, insulin, gluc)		48									48											48
60, 90 min c-pep, gluc (MMTT) / serum creat	4																					
90 min c-pep, gluc (MMTT) / serum creat											2					2			2			2
Belatacept Trough Level					2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
Atherogenic Profile		8.5																				8.5
						CENT	TRAL	MEC	HANIS	STIC	ASSAT	YS										
Alloantibody	2	2									2					2			2			2
Autoantibody		2									2					2			2			2
TAT, c-peptide & C3a			10																			
Immunogenicity samples			4												4							4
						CEN	TRAI	ARC	HIVE	D SAI	MPLE	s										
Serum		4									4					4			4			4
PBMC & Plasma		30									30					30			30			30
RNA		9									9					9			9			9
TOTALS (mls)	61.0	199.5	28.0	9.0	6.0	20.0	15.0	11.0	27.0	17.0	132.0	6.0	17.0	17.0	16.0	74.0	8.0	8.0	74.0	8.0	8.0	148.5
BL - WK 6 TOTAL (mls)	315.5																					
YEAR TOTAL (mls)	910.0					_																
TEAK TOTAL (MIS)	910.0																					

Appendix 1: Kit Supply Order Form

Protocol CIT- 04: Please complete form and fax to University of Iowa @+1-319-353-3960

Site Name & #:	 CIT Protocol:	
Shipping Address:		
Order Date:	Due Date @ Site:	
Requested By:	 Requestor's phone:	
Requestor's FAX:	Requestor's email:	

Kit(s) #	QUANTITY
Kit(s) #	

You will receive an initial supply of kits for 10 participants upon notice of your site activation. The initial supply of kits will include (1) Kit #1 through Kit # 5, per subject.

Please check your kits' expiration dates and DO NOT order more than a 6 month supply of kits.

Appendix 2: Year One Schedule of Events

Appendix 1: Year One Schedule of Events

Time points (in days relative to transplant)	SCR	WL / BL1	02	3	4	7	14	21	28	56	75	84	112	140	168	196	224	252	280	308	336	365
Visit Number	01	02	03	03a	04	05	06	07	08	09	10	11	12	13	14	15	16	17	18	19	20	21
Visit Windows (in days)	N/A	N/A	N/A	N/A	N/A	+/-2	+/-2	+/-2	+/-3	+/-3	+/-5	+/-3	+/-3	+/-3	+/-3	+/-5	+/-5	+/-5	+/-5	+/-5	+/-5	+/-5
Equivalent Week	N/A	N/A	N/A	N/A	N/A	W1	W2	W3	W4	W8	N/A	W12	W16	W20	W24	W28	W32	W36	W40	W44	W48	W52
						GI	ENER	AL AS	SESS	MEN	TS											
Informed Consent	Х3	X4																				
Med/Diabetes Hx & Demographics	х																					
Eval of Inclusion / Exclusion	х	х																				
Mammogram (females >35)	Х	X-yrly																				
Retinopathy Evaluation ⁵	Х	X-yrly ⁶																				Х
Physical Exam	Х	X-yrly	Х			Х	Х	Х	Х	Х	Х		Х	Х		Х			Х			Х
QOL		X-q3mo									Х					Х			Х			Х
Chest X-Ray	Х	X-yrly																				Х
Abdominal US (Pelvis/Liver	Х	X-yrly				Х																Х
ECG	Х	X-yrly																				Х
ECG X X-yny Image: Constraint of the second																						
PPD	Х	X-yrly																				Х
AE/Hypo Event/Toxicity Assess		х	х		x	x	х	x	x	х	x	х	x	х	x	x	x	х	х	х	x	х
					LO	CAL L	ABO	RATC	DRY A	SSES	SMEN	ITS										
CBC (WBC + Diff & Plat)	Х	X-q6mo	Х			Х	Х	Х	Х	Х	Х		Х	Х		Х			Х			Х
Chemistry ⁷	Х	Х-уарто	Х			Х	Х	Х	Х	Х	Х		Х	Х		Х			Х			Х
Lipids	Х	X-q6mo									Х					Х			Х			Х
Thyroid Function (TSH)	Х	X-yrly																				
Pregnancy test (WOCBP)	Х	X ⁸			X9		X9		X9	X9		X9	X9	X9	X9	Х9	Х9	X9	X9	X9	Х9	X9

LEA29Y Emory Edmonton Protocol (LEEP)

Time points (in days																						
relative to transplant)	SCR	WL/BL1	02	3	4	7	14	21	28	56	75	84	112	140	168	196	224	252	280	308	336	365
Visit Number	01	02	03	03a	04	05	06	07	08	09	10	11	12	13	14	15	16	17	18	19	20	21
Vīsit Windows (in days)	N/A	N/A	N/A	N/A	N/A	+/-2	+/-2	+/-2	+/-3	+/-3	+/-5	+/-3	+/-3	+/-3	+/-3	+/-5	+/-5	+/-5	+/-5	+/-5	+/-5	+/-5
Equivalent Week	N/A	N/A	N/A	N/A	N/A	W1	W2	W3	W4	W8	N/A	W12	W16	W20	W24	W28	W32	W36	W40	W44	W48	W52
				L	OCAI	LLAB	ORAT	FORY	ASSE	SSMI	ENTS	(Con'	t)									
Secology ¹⁰ (HepB/C, HIV,)	Х	X-ynły																				Х
EBVIgG	Х																					
CMVIgG,CMVIgM		X-yrly ¹¹																				X11
Coagulation (PT, PTT, INR)	Х	X-yrly	Х																			
Blood Type		X12																				
HLA		х																				
Crossmatch		X13																				
Fasting & post-prandial c- pep ¹⁴				х		х																
Glucose (immediately post-tx)			X15																			
PRA by flow cytometry		X ¹⁶																				
CMV by PCR		Х									Х				Х							
EBV by PCR17		Х																				
					CEN	TRAL	LAB	ORAT	ORY	ASSE	SSME	NTS										
First morning spot urine ¹⁸	Х	Х							Х		Х											Х
GFR	Х	X-yrly							х		Х											Х
HbA1c	Х	X-qβmo									Х					Х			Х			Х
Fasting serum gluc/c-pep & creat ¹⁹	х	х							х	x	х		х	х	х	х	x	х	x	x	х	x
Insulin modified FSIGT ¹⁹		X-yrly ⁶									Х											Х
90 min ²⁰ c-pep/gluc (MMTT) ¹⁹	х										х					х			х			x
Atherogenic Profile ²¹		х																				Х
					LC	DCAL	MET	ABOL	IC AS	SESS	MEN	ГS										
Glycemic Stability (CGMS) ¹⁹		X6									х											x

LEA29Y Emory Edmonton Protocol (LEEP)

Time points (in days																						
relative to transplant)	SCR	WL / BL ¹	02	3	4	7	14	21	28	56	75	84	112	140	168	196	224	252	280	308	336	365
Visit Number	01	02	03	03a	04	05	06	07	08	09	10	11	12	13	14	15	16	17	18	19	20	21
Visit Windows (in days)	N/A	N/A	N/A	N/A	N/A	+/-2	+/-2	+/-2	+/-3	+/-3	+/-5	+/-3	+/-3	+/-3	+/-3	+/-5	+/-5	+/-5	+/-5	+/-5	+/-5	+/-5
Equivalent Week	N/A	N/A	N/A	N/A	N/A	W1	W2	W3	W4	W8	N/A	W12	W16	W20	W24	W28	W32	W36	W40	W44	W48	W52
BSR eCRFs ^{19,22}	Х	X-q6mo									Х					Х			Х			Х
				(CALC	ULAT	ED M	IETAI	BOLIC	CASS	ESSM	ENTS	5									
MAGE		X-q6mo									Х					Х			Х			X
LI	Х	X-q6mo									Х					Х			Х			Х
Clarke Score	Х	X-q6mo														Х						Х
НҮРО	Х	X-q6mo									Х					Х			Х			Х
Beta Score		Х									X					Х			Х			X
C-peptide (gluc X creat) ratio	Х	Х							Х	Х	X		X	Х	Х	Х	Х	Х	Х	Х	X	X
					. 1	IMMU	JNOS	UPPR	ESSIC	ON LE	VELS	5										
IMMUNOSUPPRESSION LEVELS Belatacept trough levels ²³ X X																						
						N	IECH.	ANIS	TIC A	SSAY	S											
Alloantibody	х	X- q6mo ²⁴									х					x			х			х
Autoantibody ²⁵		Х									Х					Х			Х			Х
TAT, C3a, & c-peptide		Х	X ²⁶																			
Immunogenicity samples ²⁷			X ²⁸												Х							Х
			-				ARCI	IIVEL	SAM	IPLES												
Serum		Х									X					Х			Х			X
PBMC & Plasma		Х									X					Х			Х			X
RNA		Х									Х					Х			Х			X

 $^{^{1}}$ WL = Waiting List. BL = Baseline. Repeat assessments as indicated (i.e. yrly, q3mo), while subject is on the waiting list. All one-time WL/BL assessments should be completed on Day -2 whenever possible, but always prior to start of immunosuppression. For WL/BL repeat assessments, record results from test done closest to the start of immunosuppression will be used as the baseline value.

 2 Day 0 = the day of transplant.

LEA29Y Emory Edmonton Protocol (LEEP)

³ Informed consent #1 includes information on CIT04 and the multi-center Phase 3 protocol (CIT07)

⁴ Informed Consent #2 includes information specific to CIT04. IC # 2 must be signed immediately after randomization.

⁵ Retinopathy eval includes fundoscopic pictures for WL/BL assessments and Y1. Screening retinopathy evaluation should be done per site-specific standards. If pupils cannot be dilated, then a manual ophthalmologic evaluation can be substituted.

Clinical Islet Transplantation (CIT) Protocol CIT-04 CONFIDENTIAL

Page 108 of 116

⁶ These can be collected after subject is considered protocol eligible and has been moved to the transplant wait list, as time allows.

⁷ Chemistry includes: Sodium, albumin, magnesium, chloride, potassium, alk phosphatase, total bilirubin, CO₂, creatinine, ALT (SGPT), BUN, gamma GT, glucose, AST (SGOT), calcium, phosphorus

⁸ Complete serum pregnancy tests within 72 hours prior to initiation of study medication.

⁹ Complete test prior to Belatacept infusion. Confirm negative result prior to administering Belatacept

¹⁰ Serology includes: HBc Ab, HBs Ab, HBs Ag, HCV Ab, and HIV. Do not repeat Hepatitis B tests if HBs Ab was previously positive.

¹¹ Repeat only if previous test was negative.

¹² Repeat for subsequent transplant(s)

¹³ Sample used for crossmatch may be obtained up to 60 days prior to the start of immunosuppression, as long as there is no evidence of infections or transfusions since the time the sample was drawn. Repeat crossmatch for subsequent transplants.

¹⁴ C-peptide should be done locally and drawn fasting, and twice between 1-3 hrs post-prandial on Day 3 and Day 7 post-transplant.

¹⁵ Finger stick glucose should be done locally and drawn every hour for the first 6 hours immediately post-transplant.

¹⁶ Subsequent transplants only. Local result used to determine eligibility for subsequent transplants only.

¹⁷ EBV by PCR should only be done post-randomization if reactivation is suspected.

¹⁸ First morning spot urine includes: albumin, protein, and creatinine

¹⁹ Do not collect for participants with graft failure. Results of tests performed at the time of graft failure will be used for day 75 endpoint calculations.

²⁰ MMTT should include 60 and 90 minute c-peptide and glucose measurements for the screening visit and as necessary when determining graft failure.

²¹ Atherogenic profile consisting of fasting lipid panel (TG, TC, HDL, LDL, non-HDL), C reactive protein, serum amyloid A, apolipoprotein A1 and apolipoprotein B. If blood is

drawn locally, sample should be sent from local lab to study site and then shipped to the central laboratory (Univ of Washington).

²² Blood Sugar Record (BSR) eCRF is completed using information gathered from subject diary logs, glucometer download data, and insulin requirements

²³ Complete test prior to Belatacept infusion.

²⁴ For each transplant, complete alloantibody assessment every 6 months and again on Day -2, regardless of the most recent draw. Central PRA result, current within 6 months, is used to determine subject eligibility for first transplant

²⁵ Autoantibody testing includes GAD, IA-2, and IAA.

²⁶ TAT & c-peptide: pre-tx, 15, 60, 180 min post-tx

²⁷ Collect immunogenicity samples prior to belatacept infusion. For subjects that discontinue belatacept, collect additional immunogenicity samples at 4 weeks and 8 weeks post last dose.

²⁸ Collect immunogenicity sample prior to dosing with immunosuppression medications.

LEA29Y Emory Edmonton Protocol (LEEP)

Appendix 3: Continuation of Appendix 1 Schedule of Events (Subjects with Subsequent CIT Transplants)

Appendix 2: Continuation of Appendix 1 Schedule of Events (Subjects with Subsequent CIT Transplants)

Subjects who receive a subsequent islet transplant should continue their study visits according to this Schedule of Events until one year (365 +/- 5 days) after the final islet transplant. Additional visits - outlined in Appendix 3 - will also need to be completed after each subsequent transplant. After day 365 post final transplant, subjects should stop following this schedule, and complete the follow-up visits outlined in Appendix 4: Schedule of Events for 1-Year Additional Follow-Up.

Time points (in days relative to 1st transplant)	392	420	448	476	504	532	560	588	616
Visit Number	22	23	24	25	26	27	28	29	30
Vīsit Windows (in days)	±5	±5	±5	±5	±5	±5	±5	±5	±5
Equivalent Week	W56	W60	W64	W68	W72	W76	W80	W84	W88
GEN	VERAL A	SSESSM	ENTS						
Physical Exam			Х			Х			Х
QOL			Х			Х			Х
AE/Hypo Event/Toxicity Assessment	Х	Х	Х	Х	Х	Х	Х	Х	Х
LOCAL LA	BORATO	DRY AS	SESSME	NTS ¹					
CBC (WBC + Diff & Plat)			х			х			х
Chemistry ²			х			х			х
Lipids			х			х			х
Pregnancy test (WOCBP) ³	Х	х	х	х	х	х	х	х	х
CENTRAL	LABORA	TORY A	ASSESSI	MENT					
HbA1c			Х			Х			Х
Fasting serum glucose & c-peptide & serum creat ⁴	Х	Х	Х	Х	Х	Х	Х	х	Х
90 min ⁵ c-peptide/glucose (MMTT) ⁴			Х			Х			х
Atherogenic Profile6			1	year po	st-final ti	ransplan	t		
LOCAL N	/ETABOI	LIC ASS	ESSME	NTS					
BSR eCRFs47			Х			Х			Х
CALCULATE	D META	BOLIC		MENTS	6				
MAGE			Х			Х			Х
Ц			Х			X			X
Clarke Score						Х			
HYPO			Х			Х			Х

LEA29Y Emory Edmonton Protocol (LEEP)

Appendix 2: Continuation of Appendix 1 Schedule of Events (Subjects with Subsequent CIT Transplants)

Subjects who receive a subsequent islet transplant should continue their study visits according to this Schedule of Events until one year (365 +/- 5 days) after the final islet transplant. Additional visits - outlined in Appendix 3 - will also need to be completed after each subsequent transplant. After day 365 post final transplant, subjects should stop following this schedule, and complete the follow-up visits outlined in Appendix 4: Schedule of Events for 1-Year Additional Follow-Up.

Time points (in days relative to 1st transplant)	392	420	448	476	504	532	560	588	616
Visit Number	22	23	24	25	26	27	28	29	30
Vīsit Windows (in days)	±5	±5	±5	±5	±5	±5	±5	±5	±5
Equivalent Week	W56	W60	W64	W68	W72	W76	W80	W84	W88
GEN	JERAL A	SSESSM	ENTS						
Physical Exam			Х			Х			Х
QOL			Х			Х			Х
AE/Hypo Event/Toxicity Assessment	Х	Х	Х	Х	Х	Х	Х	Х	Х
LOCAL LA	BORATO	DRY AS	SESSME	NTS ¹					
CBC (WBC + Diff & Plat)			х			х			х
Chemistry ²			х			х			Х
Lipids			Х			х			х
Pregnancy test (WOCBP) ³	х	х	х	х	Х	х	х	х	х
CENTRAL	LABORA	TORY A	ASSESSI	MENT					
HbA1c			Х			Х			Х
Fasting serum glucose & c-peptide & serum creat ⁴	Х	Х	Х	Х	Х	х	х	х	Х
90 min ⁵ c-peptide/glucose (MMTT) ⁴			Х			Х			Х
Atherogenic Profile6			1	year po	st-final t	ransplan	t		
LOCAL N	ÆTABOI	LIC ASS	ESSME	NTS					
BSR eCRFs ^{4,7}			Х			х			Х
CALCULATE	D META	BOLIC	ASSESS	MENTS	6				
MAGE			Х			Х			Х
LI			Х			Х			Х
Clarke Score						Х			
HYPO			Х			X			X

LEA29Y Emory Edmonton Protocol (LEEP)

		<u></u>	<u></u>	12	2		<u></u>		<u></u>
Time points (in days relative to 1st transplant)	392	420	448	476	504	532	560	588	616
Visit Number	22	23	24	25	26	27	28	29	30
Visit Windows (in days)	±5	±5	±5	±5	±5	±5	±5	±5	±5
Equivalent Week	W56	W60	W64	W68	W72	W76	W80	W84	W88
CALCULATED MI	ETABOLI	C ASSES	SMEN	IS (cont	inued)				
Beta Score			Х			Х			Х
C-peptide (glucose X creatinine) ratio	Х	Х	Х	Х	Х	Х	Х	Х	Х
IMMU	NOSUPPH	RESSION	I LEVE	LS	10	10			
Belatacept trough levels ⁸	Х	X	Х	Х	Х	X	Х	Х	Х
M	ECHANIS	STIC AS	SAYS						
Alloantibodies ⁹			Х			Х			Х
Autoantibodies ¹⁰			X			Х			Х
Immunogenicity samples ¹¹						X			
A	RCHIVEI	D SAMP	LES						
Serum			Х			Х			Х
PBMC & Plasma			Х			Х			Х
RNA			Х			Х			Х

¹ EBV by PCR should only be done post-randomization if reactivation is suspected.

⁷Blood sugar Record (BSR) eCRF is completed using information gathered from subject diary logs, glucometer download data, and insulin requirements.

⁸ Complete test prior to Belatacept infusion. For pregnancy test, confirm negative result prior to administering Belatacept.

⁹ For each transplant, complete alloantibody assessment every 6 months and again on Day -2, regardless of the most recent draw.

¹⁰ Autoantibody testing includes GAD, IA-2, and IAA.

¹¹ Collect immunogenicity samples prior to belatacept infusion. For subjects that discontinue belatacept, collect additional immunogenicity samples at 4 weeks and 8 weeks post last dose.

² Chemistry includes: Sodium, albumin, magnesium, chloride, potassium, alk phosphatase, total bilirubin, CO₂, creatinine, ALT (SGPT), BUN, gamma GT, glucose, AST (SGOT), calcium, phosphorus

³ Confirm negative result prior to administering Belatacept.

⁴ Also collect as necessary to perform graft failure. Do not collect after graft failure has been confirmed.

⁵ MMTT should include 90 minute c-peptide and glucose measurements, add 60 minute as necessary when determining graft failure.

⁶ Atherogenic profile consisting of fasting lipid panel (TG, TC, HDL, LDL, non-HDL), C reactive protein, serum amyloid A, apolipoprotein A1 and apolipoprotein B. If blood is drawn locally, sample should be sent from local lab to study site and then shipped to the central laboratory (Univ of Washington).

Appendix 4: Subsequent Transplant Schedule of Events

Appendix 3: Subsequent Transplant Schedule of Events

The following immediate post-transplant and endpoint assessments should be completed for subjects who receive a subsequent islet transplant. If any of the visits below fall within an acceptable window of a follow-up visit on the Year One Schedule of Events (Appendix 1) or Year Two Schedule of Events (Appendix 2), the assessments may be added to that follow-up visit so that a separate visit does not need to occur.

This point (a) the p	Time point (in days relative to most recent infusion)	01	3	4	7	75	365
Visit Window (in days)N/AN/AN/AN/AV/AV/AV/AV/AV/3V/3V/3V/3Equivalent Week (post most recent infusion)N/AN/AN/AN/AW1N/AW3W32GENERAL ASSESSMENTSXXXXXXXXQOLIIIIXXXXXXChest X-RayIIIIXX </td <td>• • •</td> <td>-</td> <td>-</td> <td>-</td> <td></td> <td></td> <td></td>	• • •	-	-	-			
Equivalent Week (post most recent infusion)N/AN/AN/AW1N/AW32GENERAL ASSESSMENTSPhysical EvamXXXXQOLIIXXXChest X-RayIIIXXXAbdoninal US (Pelvis/Liver)IIIXXXPEDIIIXXXXAE/Hypo Event/Toxicity AssessXXXXXCOCAL LABORATORY ASSESSMENTSCBC (WBC + Diff & Plat)XIXXXLipidsXXXXXLipidsIIXXXCoagulation (PT, PTT, INR)XIIIIBlood Type & HLAX ⁰ IIIIIRAb flow cytometryX ³ IIIIIPRA by flow cytometryX ³ IIIIIPregancy test (WOCEP) ⁶ XIIXXXCMV by PCR*IIIIXXXAsting senunghacos/coeptide & creat ¹¹ IIIXXXAsting senunghacos/coeptide & creat ¹¹ IIIXXXAsting senunghacos/coeptide & creat ¹¹ IIIXXXAsting senunghacos/coeptide & creat ¹¹ IIIX							
GENERAL ASSESSMENTSImage of the symbol sym					· ·		-
Physical ExamXXXXXQOLIIXXXQOLIIXXXChest X-RayIIXXXAbdominal US (Pelvis/Liver)IXXXXECGIIXXXXPPDIIXXXXAE/Hypo Event/Toxicity AssessXXXXXXCOCAL LABORATORY ASSESSMENTSIXXXXChemistry:XXXXXXChemistry:XIXXXXCoagulation (PT, PTT, INR)XIIIIBlood Type & HLAX ⁰ IIIICrossmatchX ⁴ IIIIIPregnancy test (WOCBP) ⁶ XXXXIGhrcose (immediately post-transplant) ⁷⁷ XIIIPregnancy test (WOCBP) ⁶ XIXXXGFRIIXXXIHbA1cIIIXXXPasting senun ghacos/c-peptide & creat ¹¹ IIXXInsulin modified PSIGT ¹¹ IIXXSetter profile ¹² IIXXPisting senun ghacos/c-peptide & creat ¹¹ IXXReffI <t< td=""><td></td><td></td><td>IN/A</td><td>IN/A</td><td>**1</td><td>N/A</td><td>1132</td></t<>			IN/A	IN/A	**1	N/A	1132
QÓL Image: State of the second s					X	X	X
Chest X-RayImage: Chest X-RayImage: Chest X-RayXXXAbdominal US (Pelvis/Liver)XXXXXECGImage: Chest X-RayXXXXPPDImage: Chest X-RayXXXXXAE/Hypo Event/Toxicity AssessXXXXXXCBC (WBC + Diff & Plat)XXXXXXXCBC (WBC + Diff & Plat)XXXXXXXLipidsXXXXXXXXLipidsXXXXXXXCosgulation (PT, PTT, INR)XImage: Chest X-RayImage: Chest X-RayImage: Chest X-RayImage: Chest X-RayBlood Type & HLAX ⁴ XXXImage: Chest X-RayImage: Chest X-RayImage: Chest X-RayCorosmatchX ⁴ XXXXImage: Chest X-RayImage: Chest X-RayImage: Chest X-RayPRA by flow cytometryX ⁵ XXXImage: Chest X-RayImage: Chest X-RayImage: Chest X-RayPregnancy test (WOCEB) ⁶ XXXXImage: Chest X-RayImage: Chest X-RayCMV by PCR ⁵ Image: Chest X-RayXXXXCMV by PCR ⁵ Image: Chest X-RayImage: Chest X-RayXXGFRImage: Chest X-RayImage: Chest X-RayXXIbhAltImage: Chest X		~			~		
Abdominal US (Pelvis/Liver) X X X ECG X X X PPD X X X AE/Hypo Event/Toxicity Assess X X X X LOCAL LABORATORY ASSESSMENTS X X X X CBC (WBC + Diff & Plat) X X X X X Chemistry ² X X X X X X Lipids X X X X X X Coagulation (PT, PTT, INR) X X X X X Blood Type & HLA X ³ X X X X PRA by flow cytometry X ³ X X X Glucose (immediately post-transplant) ⁷ X X X X Pregnancy test (WOCBP) ⁶ X X X X Glucose (inmediately post-transplant) ⁷ X X X X Pregnancy test (WOCBP) ⁶ X X X X X GRe X X X<	7					~	
ECG Image: Constraint of the second sec					x		
PPD Image: constraint of the second sec					~		
AE/Hypo Event/Toxicity AssessXXXXXXLOCAL LABORATORY ASSESSMENTSCBC (WBC + Diff & Plat)XXXXXChemistry2XXXXXXChemistry2XXXXXXLipidsXXXXXXCoagulation (PT, PTT, INR)XXXXXBlood Type & HLAX ⁰ XXXXCrossmatchX ⁴ XXXXPRA by flow cytometryX ⁵ XXXPasting & post-prandial c-peptide ⁶ XXXXGlucose (immediately post-transplant)?XXXXCMV by PCR ⁵ XXXXXCMV by PCR ⁵ XXXXXFirst moming spot urine ¹⁰ XXXXGFRIXXXXHbA1cIIXXXArthrogenic Profile ¹² IXXX90 min c-pep/glucose (MMTI) ¹¹ IIXXXBSR eCRF9 ^{11,13} IIXXXMAGEIXXXXIJCALCULATED METABOLIC ASSESSXXXHYPOIIXXX							
LOCAL LABORATORY ASSESSMENTSCBC (WBC + Diff & Plat)XXXXChemistry2XXXXLipidsXXXXCoagulation (PT, PTT, INR)XXXXBlood Type & HLAX1XXXCrossmatchX4X4XXPRA by flow cytometryX5XXXPasting & post-prandial c-peptide*XXXXGlucose (immediately post-transplant)?XXXXCMV by PCR*XXXXXFirst moming spot urine ¹⁰ XXXXGFRXXXXXAthon and the open cols (MMTT) ¹¹ XXXArthrogenic Profile ¹² XXXXSin cols (MMTT) ¹¹ XXXXMAGEXXXXXHDACXXXXHYPOXXXXHYPOXXXX		X		х	х	х	
CBC (WBC + Diff & Plat)XXXXXChemistry2XXXXXXLipidsXXXXXXCoagulation (PT, PTT, INR)X </td <td></td> <td></td> <td>ENTS</td> <td>~</td> <td></td> <td></td> <td></td>			ENTS	~			
Chemistry? X X X X X X X X Lipids X X X X X X X Coagulation (PT, PTT, INR) X X X X X X Blood Type & HLA X ³ X X X X X Crossmatch X ⁴ X X X X X PRA by flow cytometry X ⁵ X X X X Glucose (immediately post-transplant) ⁷ X X X X Off by PCR ⁹ X X X X X CMV by PCR ⁹ X X X X X Chart of the post-transplant (VOCEP) ⁶ X X X X CMV by PCR ⁹ X X X X X CMV by PCR ⁹ X X X X X GFR X X X X X Hasting serum glucose/copeptide & creat ¹¹ X X X X		-			х	Х	х
Coagulation (PT, PTT, INR)XIIIBlood Type & HLAX³IIIIBlood Type & HLAX³IIIICrossmatchX4IIIIIPRA by flow cytometryX5IIIIFasting & post-prandial c-peptide ⁶ XXXIIGlucose (immediately post-transplant)?XIIIXPregnancy test (WOCBP) ⁶ XIIXXCMV by PCR*IIXXXFirst moming spot urine ¹⁰ XIXXXGFRIIXXXHbA1cIIXXXFasting serum glucose/c-peptide & creat ¹¹ IIXX90 minc-pep/glucose (MMT) ¹¹ IIXXArtherogenic Profile ¹² IIXXGlycemic Stability (CGMS) ¹¹ IXXXBSR eCRFs ^{11,33} IIXXMAGEIIXXXHYPOIIIXXHYPOIIIXX		X			Х		X
Coagulation (PT, PTT, INR)XIIIBlood Type & HLAX³IIIIBlood Type & HLAX³IIIICrossmatchX4IIIIIPRA by flow cytometryX5IIIIFasting & post-prandial c-peptide ⁶ XXXIIGlucose (immediately post-transplant)?XIIIXPregnancy test (WOCBP) ⁶ XIIXXCMV by PCR*IIXXXFirst moming spot urine ¹⁰ XIXXXGFRIIXXXHbA1cIIXXXFasting serum glucose/c-peptide & creat ¹¹ IIXX90 minc-pep/glucose (MMT) ¹¹ IIXXArtherogenic Profile ¹² IIXXGlycemic Stability (CGMS) ¹¹ IXXXBSR eCRFs ^{11,33} IIXXMAGEIIXXXHYPOIIIXXHYPOIIIXX						Х	Х
Blood Type & HLAX3Image: Constraint of the second s		х					
CrossnatchX4Image: Constraint of the second s		X3					
Fasting & post-prandial c-peptide6XXXIGlucose (immediately post-transplant)7XIIXPregnancy test (WOCBP)8XIXXCMV by PCR9IIXXXCENTRAL LABORATORY ASSESSMENTSIXXXFirst moming spot urine10IIXXXGFRIIXXXHbA1cIIXXXFasting senunghcose/c-peptide & creat ¹¹ IIXXInsulin modified PSIGT ¹¹ IIXX90 minc-pep/glucose (MMIT) ¹¹ IIXXOrecter IOCAL METABOLIC ASSESSMENTSIXXGlycennic Stability (CGMS) ¹¹ IIXXDAGEIIXXXMAGEIIIXXIIIIIXXHYPOIIIXX		X4					
Fasting & post-prandial c-peptide6XXXIGlucose (immediately post-transplant)7XIIXPregnancy test (WOCBP)8XIXXCMV by PCR9IIXXXCENTRAL LABORATORY ASSESSMENTSIXXXFirst moming spot urine10IIXXXGFRIIXXXHbA1cIIXXXFasting senunghcose/c-peptide & creat ¹¹ IIXXInsulin modified PSIGT ¹¹ IIXX90 minc-pep/glucose (MMIT) ¹¹ IIXXOrecter IOCAL METABOLIC ASSESSMENTSIXXGlycennic Stability (CGMS) ¹¹ IIXXDAGEIIXXXMAGEIIIXXIIIIIXXHYPOIIIXX	PRA by flow cytometry	X5					
Glucose (immediately post-transplant)?XIIIPregnancy test (WOCBP)8XIXXCMV by PCR8IIXXCENTRAL LABORATORY ASSESSMENTSIXXFirst morning spot urine10IXXGFRIXXXHbA1cIIXXFasting serum glucose/c-peptide & creat ¹¹ IIXXInsulin modified PSIGT ¹¹ IIXX90 min c-pep/glucose (MMIT) ¹¹ IIXX90 min c-pep/glucose (MMIT) ¹¹ IIXXSer eCRFs ^{11,13} IXXXBSR eCRFs ^{11,13} IXXXMAGEIXXXIIIIXXXHYPOIIIXX			Х		Х		
Pregnancy test (WOCBP)®XIIXIXCMV by PCR®IIIXXCENTRAL LABORATORY SESSMENTSIXXFirst moming spot urine®IIIXXGFRIIIXXXGFRIIIXXXHbA1cIIIXXXFasting serunghcose/c-peptide & creat®IIXXXInsulin modified PSIGT ¹¹ IIIXX90 minc-pep/ghcose (MMITI)®IIIXX90 minc-pep/ghcose (MMITI)®IIIXXSterre Profile®IIIIXXGlycemic Stability (CGMS)%IIIIXXMAGEIIIIXXXHMAGEIIIIXXHYPOIIIIXXHYPOIIIIIXX	Glucose (immediately post-transplant) ⁷	Х					
CENTRAL LABORATORY ASSESSMENTSFirst moming spot urine ¹⁰ XXGFRXXXGFRXXXHbA1cXXXFasting serum glucose/c-peptide & creat ¹¹ XXXInsulin modified PSIGT ¹¹ XXX90 min c-pep/glucose (MMIT) ¹¹ XXX90 min c-pep/glucose (MMIT) ¹¹ XXXSerecre (Profile ¹²)XXXGlycemic Stability (CGMS) ¹¹ XXXCALCULATED METABOLIC ASSESSMENTSMAGEXXXIIXXXIIXXXHYPOXXXHYPOXXX	Pregnancy test (WOCBP) ⁸	Х					Х
First moming spot urine10IIIXXGFRIIIXXHbA1cIIXXXFasting serum glucose/c-peptide & creat ¹¹ IIXXInsulin modified PSIGT ¹¹ IIXX90 min c-pep/glucose (MMTT) ¹¹ IIXX90 min c-pep/glucose (MMTT) ¹¹ IIXX90 min c-pep/glucose (MMTT) ¹¹ IIXXSere CPFs ^{11,13} IIXXCALCULATED METABOLIC ASSESSMENTSMAGEIXXLIIXXLIIXXHYPOIXXHYPOIXX	CMV by PCR ⁹					Х	
GFRIIIXXHbA1cIIIIXXFasting serum glucose/c-peptide & creat ¹¹ IIIXXInsulin modified PSIGT ¹¹ IIIXX90 min c-pep/glucose (MMITT) ¹¹ IIIXXArtherogenic Profile ¹² IIIXXGlycemic Stability (CGMS) ¹¹ IIIXXBSR eCRFs ^{11,13} IIXXXMAGEIIXXXLIIIIXXHYPOIIIXX	CENTRAL LABORATORY A	SSESSN	IENTS				
GFRIIIXXHbA1cIIIIXXFasting serum glucose/c-peptide & creat ¹¹ IIIXXInsulin modified PSIGT ¹¹ IIIXX90 min c-pep/glucose (MMITT) ¹¹ IIIXXArtherogenic Profile ¹² IIIXXGlycemic Stability (CGMS) ¹¹ IIIXXBSR eCRFs ^{11,13} IIXXXMAGEIIXXXLIIIIXXHYPOIIIXX	First morning spot urine ¹⁰					Х	Х
Fasting serum glucose/c-peptide & creat ¹¹ Image: Serum glucose/c-peptide & creat ¹						Х	Х
Insulin modified PSIGT ¹¹ X X 90 min c-pep/glucose (MMIT) ¹¹ X X Artherogenic Profile ¹² A X <u>LOCAL METABOLIC ASSESSMENTS</u> Glycemic Stability (CGMS) ¹¹ X X BSR eCRFs ^{11,13} X X <u>CALCULATED METABOLIC ASSESSMENTS</u> MAGE X X X LI Clarke Score X X X HYPO	HbA1c					Х	Х
Insulin modified PSIGT ¹¹ X X 90 min c-pep/glucose (MMIT) ¹¹ X X Artherogenic Profile ¹² A X <u>LOCAL METABOLIC ASSESSMENTS</u> Glycemic Stability (CGMS) ¹¹ X X BSR eCRFs ^{11,13} X X <u>CALCULATED METABOLIC ASSESSMENTS</u> MAGE X X X LI Clarke Score X X X HYPO	Fasting serum glucose/c-peptide & creat ¹¹					Х	Х
Artherogenic Profile ¹² Image: Constraint of the image: Constrain						х	х
Artherogenic Profile ¹² Image: Constraint of the image: Constrain	90 min c-pep/shucese (MMTT)#					х	Х
LOCAL METABOLIC ASSESSMENTS Glycemic Stability (CGMS) ¹¹ X X BSR eCRFs ^{11,13} X X X CALCULATED METABOLIC ASSESSMENTS MAGE X X LI X X X Clarke Score X X X HYPO X X X							
Glycemic Stability (CGMS) ¹¹ X X BSR eCRFs ^{11,13} I I X X CALCULATED METABOLIC ASSESSMENTS MAGE I X X LI I X X Clarke Score I I I X HYPO I X X		ASSES	SMENT	2			~
BSR eCRFs ^{11,13} X X CALCULATED METABOLIC ASSESSMENTS MAGE X X X LI X X Clarke Score X X X HYPO X X X		10010		<u> </u>		х	Х
CALCULATED METABOLIC ASSESSMENTS MAGE X X LI X X Clarke Score X X HYPO X X							
MAGE X X LI X X Clarke Score X X HYPO X X		LICAS	SESSM	ENTS			
LI Image: Clarke Score X X Clarke Score Image: Clarke Score X X HYPO X X X						Х	Х
Clarke Score Image: Clarke Score X HYPO X X							
HYPO X X	Clarke Score						
Beta Score X X						Х	Х
	Beta Score					Х	Х

LEA29Y Emory Edmonton Protocol (LEEP)

Time point (in days relative to most recent infusion)	01	3	4	7	75	365
Visit Number	TBD	TBD	TBD	TBD	TBD	TBD
Visit Window (in days)	N/A	N/A	N/A	+/-3	+/-5	+/-14
Equivalent Week (post most recent infusion)	N/A	N/A	N/A	W1	N/A	W52
CALCULATED METABOLIC ASSES	SSMENT	ΓS (cont	inued)			
C-peptide glucose creatinine ratio					Х	Х
IMMUNOSUPPRES	SION L	EVELS				
Belatacept trough levels ¹⁴			Х	Х	Х	х
MECHANISTIC AS	SAYS					
Alloantibody ¹⁵	х				X	х
Autoantibody ¹⁶					Х	Х
TAT, C3a, & c-peptide	X17					
Immunogenicity samples ¹⁸						Х
ARCHIVED SAME	PLES					
Serum					х	х
PBMC & Plasma					Х	х
RNA					Х	х

¹ Day 0 = the day of transplant.

² Chemistry includes: Sodium, albumin, magnesium, chloride, potassium, alk phosphatase, total bilirubin,

CO2 creatinine, ALT (SGPT), BUN, gamma GT, glucose, AST (SGOT), calcium, phosphorus

³ Repeat for subsequent transplant(s).

⁴ Sample used for crossmatch may be obtained up to 60 days prior to islet infusion, as long as there is no evidence of infections or transfusions since the time the sample was drawn.

⁵ PRA by flow cytometry should be performed locally prior to any subsequent transplant. Local result used to determine eligibility for subsequent transplants only.

⁶ C-peptide should be done locally and drawn fasting, and twice between 1-3 hrs post-prandial on Day 3 and Day 7 post-transplant.

⁷ Finger stick glucose should be done locally and drawn every hour for the first 6 hours immediately posttransplant.

⁸ Perform pregnancy test and confirm negative result prior to each belatacept infusion.

⁹ EBV by PCR should only be done post-randomization if reactivation is suspected.

¹⁰ First morning spot urine includes: albumin, protein, and creatinine.

¹¹ Also collect as necessary to confirm graft failure. Do not collect after graft failure has been confirmed.

¹² Atherogenic profile consisting of fasting lipid panel (TG, TC, HDL, LDL, non-HDL), C reactive protein, serum amyloid A, apolipoprotein A1 and apolipoprotein B. If blood is drawn locally, sample should be sent from local lab to study site and then shipped to the central laboratory (Univ of Washington).

¹³ Blood Sugar Record (BSR) eCRF is completed using information gathered from subject diary logs, glucometer download data, and insulin requirements.

¹⁴ Complete test prior to belatacept infusion. For pregnancy test, confirm negative result prior to administering belatacept.

¹⁵ For each transplant, complete alloantibody assessment every 6 months and again on Day -2, regardless of the most recent draw.

16 Autoantibody testing includes GAD, IA-2, and IAA.

17 TAT & c-peptide: pre-infusion, 15, 60, and 180 min post-infusion.

¹⁸ Collect immunogenicity samples prior to belatacept infusion. For subjects that discontinue belatacept, collect additional immunogenicity samples at 4 weeks and 8 weeks post last dose.

LEA29Y Emory Edmonton Protocol (LEEP)

Appendix 5: Schedule of Events for 1-Year Additional F/U

Appendix 4: Schedule of Events for 1-Year Additional Follow-Up

Time point (Equivalent weeks after	W4	W8	W12	W16	W20	W24	W28	W32	W36	W40	W44	W48	W52	Y21
'Day 365 post final transplant' visit)	(AY)	(AY)	(AY)	(AY)	(AY)	(AY)	(AY)	(AY)	(AY)	(AY)	(AY)	(AY)	(AY)	(AY)
Visit Number (relative to final islet	51	52	53	54	55	56	57	58	59	60	61	62	63	64
transplant)														
Visit Window (specified in days)	±5	±5	±5	±5	±5	±5	±5	±5	±5	±5	±5	±5	±5	±30
GENERAL ASSESSMENTS														
Physical Exam						X							X	X
Telephone Consult			Х							Х				
QOL													Х	Х
AE /Hypoglycemic Events/Toxicity			х			х				х			х	х
Assessment			^			^				^			~	^
		LC	CAL L	ABORA	TORY	ASSESS	MENT	s						
CBC (WBC + Diff & Plat)			Х			Х				Х			Х	
Chemistry ²			Х			Х				Х			Х	
Lipids						Х							Х	
Pregnancy test (WOCBP) ³	Х	х	Х	Х	Х	Х	Х	Х	х	Х	Х	Х	Х	
		CEN	TRAL	LABOR	ATORY	ASSES	SMEN	TS						
First morning spot urine4						Х							Х	
GFR													Х	
HbA1c			X5			Х				X5			Х	Х
90-min c-pep/glucose (MMTT) ²						Х							Х	Х
Atherogenic Profile													Х	
LOCAL METABOLIC ASSESSMENTS														
Glycemic Stability (CGMS) ²													Х	Х
Clinical Islet Transplantation (CIT) Protocol CIT-04				-	CONFI	DENTL	AL			-	-	Pag	e 113 of	116

¹ Two years post initial transplant.

² Also collect as necessary to confirm graft failure. Do not collect after graft failure is confirmed.

LEA29Y Emory Edmonton Protocol (LEEP)

Time point (Equivalent weeks after	W4	W8	W12	W16	W20	W24	W28	W32	W36	W40	W44	W48	W52	Y21
'Day 365 post final transplant' visit)	(AY)													
Visit Number (relative to final islet	51	52	53	54	55	56	57	58	59	60	61	62	63	64
transplant)														
Visit Window (specified in days)	±5	±5	±5	±5	±5	±5	±5	±5	±5	±5	±5	±5	±5	±30
CALCULATED METABOLIC ASSESSMENTS														
Clarke Score													Х	
IMMUNOSUPPRESSION LEVELS														
Belatacept Trough Levels	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	
MECHANISTIC ASSAYS														
Autoantibody						Х							Х	
MECHANISTIC ASSAYS (Cont'd)														
Alloantibody						Х							Х	
Immunogenicity Samples													Х	Х

¹ Since belatacept is infused every 28 days, an additional infusion visit will be required during the second year. Since the timing is dependent on final transplant date, this visit can be shifted as needed.

³ Perform pregnancy test and confirm negative result prior to each belatacept infusion.

4 First morning spot urine includes: albumin, protein, and creatinine.

⁵ Can be drawn locally.

LEA29Y Emory Edmonton Protocol (LEEP)

² Chemistry includes: Sodium, albumin, magnesium, chloride, potassium, alk phosphatase, total bilirubin, CO2, creatinine, ALT (SGPT), BUN, gamma GT, glucose, AST (SGOT), calcium, phosphorus.

Appendix 6: Supply Order Form: Bulk Supply (shipping supplies)

11010001011-99.1	lease complete form and f	ax to University of Iowa	@+1-313-333-3900
Site Name & #:		CIT Protocol:	
Shipping Address:		·	
Order Date:		Due Date @ Site:	
Requested By:		Requestor's phone:	
Requestor's FAX:		Requestor's email:	

SHIPPING SUPPLIES					
Shipping Container – ambient kit					
Shipping Container – refrigerated kit					
Shipping Container – frozen kit					
STP-317 ambient gel packs					
FedEx Airbills to University of Washington—DRY ICE					
FedEx Airbills to University of Washington—COLD PACK					
FedEx Airbills to University of Pennsylvania					
FedEx Airbills to Barbara Davis Center					
FedEx Airbills to Rudbeck Laboratory					
FedEx Airbills to NIDDK Repository					
FedEx Airbills to ITN Central Cell Processing Core Facility					
FedEx Airbills to ITN RNA Isolation Core Facility					
FedEx Airbills to University of Minnesota					
FedEx Airbills to Tandem Lab					
FedEx Airbills to PPD					

Protocol CIT-99: Please complete form and fax to University of Iowa @+1-319-353-3960